 EMERYVILLE, Calif., March 08, 2021 GLOBE NEWSWIRE -- Gritstone Oncology, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its leadership team. Karin Jooss, Ph.D., previously the companys executive vice president of research and chief scientific officer, has been appointed to the position of head of research and development. Erin Jones, M.S., who served as the companys executive vice president of global regulatory affairs and quality, has been appointed to the position of chief operating officer COO. 